matejmo/E+ by way of Getty Images
- Patients handled with Invivyd’s (NASDAQ:IVVD) Pemgarda (pemivibart) confirmed an 84% relative risk reduction in symptomatic COVID-19 in comparison with placebo in a part 3 trial.
- In a bunch of all-comer immunocompetent people, 1.9% of handled people in a 180-day time interval developed symptomatic COVID. in comparison with 11.9% within the placebo group.
- Pemgarda at present has Emergency Use Authorization from the U.S. FDA for COVID pre-exposure prophylaxis.
- Despite the outcomes, shares are off 18%.
Source: Seekingalpha